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Background: A substantial body of research has established the effectiveness of brief interventions for problem
alcohol use. Following these studies, national dissemination projects of screening, brief intervention (BI), and referral
to treatment (SBIRT) for alcohol and drugs have been implemented on a widespread scale in multiple states despite
little existing evidence for the impact of BI on drug use for non-treatment seekers. This article describes the design
of a study testing the impact of SBIRT on individuals with drug problems, its contributions to the existing literature,
and its potential to inform drug policy.
Methods/design: The study is a randomized controlled trial of an SBIRT intervention carried out in a primary care
setting within a safety net system of care. Approximately 1,000 individuals presenting for scheduled medical care at
one of seven designated primary care clinics who endorse problematic drug use when screened are randomized in
a 1:1 ratio to BI versus enhanced care as usual (ECAU). Individuals in both groups are reassessed at 3, 6, 9, and 12
months after baseline. Self-reported drug use and other psychosocial measures collected at each data point are
supplemented by urine analysis and public health-related data from administrative databases.
Discussion: This study will contribute to the existing literature by providing evidence for the impact of BI on
problem drug use based on a broad range of measures including self-reported drug use, urine analysis, admission
to drug abuse treatment, and changes in utilization and costs of health care services, arrests, and death with the
intent of informing policy and program planning for problem drug use at the local, state, and national levels.
Trial registration: ClinicalTrials.gov NCT00877331
Keywords: Problem drug use, Screening, Brief Intervention and Referral to Treatment (SBIRT), Motivational
Interviewing (MI), Addiction Severity Index (ASI), Safety net, Public health benefit, Cost effectivenessBackground
A substantial body of research has established the effi-
cacy and effectiveness of brief (one to two sessions)
interventions (BI) for excessive or hazardous alcohol use
in patients seen in medical settings, both primary care
and emergency department (ED) [1-3]. Following these
studies, national dissemination projects of screening,
brief intervention, and referral to treatment (SBIRT) for
alcohol and drugs have been implemented on a* Correspondence: krupski@u.washington.edu
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reproduction in any medium, provided the orwidespread scale in multiple states [4,5]. Some have
argued that this rapid progression of BI from efficacy to
effectiveness to dissemination for drugs other than alco-
hol has outstripped its evidence base [6]. For example,
there have been few randomized controlled trials of BI
for drug abuse in the general medical setting for non-
treatment seekers [7,8], leading the US Preventative Ser-
vices Task Force to conclude that the utility of BI in
medical settings as an opportunistic intervention for
drug abuse remains unclear [9]. Thus, from a policy per-
spective, an important but still unanswered question is
whether BI reduces drug use.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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portionate number of individuals with drug abuse or de-
pendence are from lower socioeconomic strata [10],
where access to specialized substance abuse treatment is
difficult and, as a result, exacerbates the motivational
challenges and follow-through that BI targets. Such indi-
viduals, who are often uninsured or on Medicaid, face
daunting and diverse barriers to health care access and
are usually served in public sector safety net medical set-
tings (hospitals and community health clinics). Few of
these individuals seek specialist chemical dependency
treatment [11]. The related costs of untreated drug
abuse are substantial [12-14]. Updated data on such
costs and public health-related adverse effects are
needed by policymakers to create the necessary traction
to drive policy changes to improve provision of drug
treatment. In this regard, ambulatory primary care is an
important setting to test the effectiveness of BI on drug
abuse since, were it effective, modest effects for a large
number of patients would yield a sizable public health
benefit [15].
Accordingly, this study was designed to evaluate the
impact of a BI on patients with problem drug use in a
primary care setting within a safety net system of care. It
is intended to serve as a policy-relevant randomized
controlled trial with broad external validity. It builds
upon the significant knowledge base acquired in the
study of brief interventions in medical settings for alco-
hol abuse including a well-documented intervention uti-
lizing motivational interviewing (MI) [16-18] and a
growing literature that focuses on public health out-
comes of BI [19,20]. It is unusual in its focus on provid-
ing BIs to individuals with evidence of drug dependence
and abuse in primary care. As such, its design and im-
plementation has required consideration of a number of
factors that, prior to this point in time, have not been
relevant to the study of BIs. The purpose of this paper is
to describe the design as well as the rationale for key
decisions made in this study with the intent of informing
future studies with a focus on BI in drug abuse.
Methods and design
Specific aims
The primary focus of the study is to evaluate the impact
of a BI on patients with problem drug use and abuse
seen in a primary care clinic at a large safety net hospital
by comparing outcomes among patients randomly
assigned to one of two conditions: (i) BI, consisting of
one encounter during a routine primary care medical
visit with a brief follow-up phone booster and referral to
treatment when indicated; and (ii) enhanced care as
usual (ECAU) consisting of problem notification and re-
ferral during a routine primary care medical visit. Spe-
cific aims are to: (1) Examine whether BI is effectivecompared to ECAU at reducing drug use and improving
psychiatric and select psychosocial outcomes in indivi-
duals with a spectrum of problem drug use; (2) Test
whether interventionist fidelity to the BI model is asso-
ciated with better outcomes; (3) Estimate the impact of
the BI on several public health outcomes that are di-
rectly related to the hazardous effects of illicit drug use
including the use of acute health care services, involve-
ment in the criminal justice system, HIV risk behavior,
and mortality; and (4) Estimate the costs of the interven-
tion, potential cost offsets, and its incremental cost-
effectiveness from the payer perspective based on health
care service use and drug use frequency.
Study design
This study is a two-group randomized prospective trial
with blinded assessments (See Figure 1), approved by
the University of Washington Institutional Review Board
(Protocol #34892). Written informed consent is obtained
from patients for study participation including permis-
sion to use unidentified information collected from them
in study reports. Approximately 1,000 individuals pre-
senting for scheduled medical care at one of seven desig-
nated primary care clinics who endorse problematic
drug use when screened during that visit and then ran-
domized in a 1:1 ratio to BI versus ECAU using a strati-
fied permuted block randomization procedure. The
purpose of the stratification is to balance random assign-
ment by three factors known to be related to substance
abuse outcomes including severity of drug problem [21],
presence of a co-occurring mental disorder [22], and
readiness to change [23].
Individuals randomized to the BI group receive screen-
ing, a single-encounter BI with referral to treatment
when indicated, and a single follow-up phone contact
approximately one week later. Individuals assigned to
ECAU receive screening, a handout with the results of
their drug screen, the risk associated with their drug use,
and a list of referrals to chemical dependency treatment.
Individuals in both groups are re-assessed at 3, 6, 9, and
12 months after baseline. All assessments are carried out
in person wherever possible, with phone interview as a
back-up option. Persons conducting follow-up assess-
ments are blinded to the participant’s intervention ver-
sus control group assignment.
Two-arm design: BI versus usual care
A two-arm design was adopted in order to assess the
effects of the BI over and above usual care. However, the
clinic sites where recruitment takes place for this study
offer patients more options than may be available in
other safety net medical settings across the country. This
fact coupled with the ethical need to provide referral fol-
lowing screening of dependent patients led to defining
Approach and Screening (5 minutes/patient)
Consent & Contact Information (20 minutes)
Baseline Assessment (30 minutes)
Randomization (5 minutes)
Enhanced Care as Usual condition
• Drug Abuse Screen Test (DAST-10) results
• List of chemical dependency treatment 
resources
Brief Intervention condition
• Brief intervention (30 minutes) 
• Drug Abuse Screening Test (DAST-10) results
• List of chemical dependency treatment 
resources if MI-consistent
1 booster call approximately 1 week
post intervention (10 minutes)
3-month Assessment (30 minutes)
6-month Assessment (30 minutes)
9-month Assessment (30 minutes)
12-month Assessment (30 minutes)
Figure 1 Study design.
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a test of whether BI is better than a less expensive but
relatively high quality usual-care option, as opposed to
being better than no intervention at all (neither system-
atic screening nor follow-up of screen-positive patients)
and, as such, represents a rigorous comparison.
Influence of the SAMHSA SBIRT dissemination program
Washington State received an SBIRT grant from the Sub-
stance Abuse and Mental Health Services Administration
(SAMHSA) in 2003 that placed chemical dependency
professionals trained in BI and associated MI skills into
the emergency departments (EDs) of nine hospitals
across the state (“WASBIRT”) [20]. The site of the
current study is one of these hospitals. In order to build
upon the strengths of these WASBIRT ED services and
to maintain consistency with them, the current study is
set up to mirror the WASBIRT design to the extent that
is both reasonable and possible. This includes using the
Drug Abuse Screening Test (DAST-10) to estimate drug
use severity, using physician extenders to deliver the
intervention, and using a single 30–45 minute BI session.When SAMHSA funding ended in 2008, local
resources were made available to sustain SBIRT services
in the ED at the site of the current study. This created
two potential confounds. One, enrolled patients may re-
ceive a previous BI, and two, they may receive a subse-
quent BI. To control for these potential confounds, we
use administrative data. Subsequent exposure is used as
an outcome because those receiving a BI in the current
study might be more open to receive an additional one,
suggesting a useful metric for assessing intervention
value.
Defining the population
As stated earlier, the population of interest is individuals
seeking primary care treatment in a safety net medical
center setting. Screening procedures are designed to
identify individuals with problem drug use along a con-
tinuum of severity. Study inclusion criteria include
adults age 18 and over; having used an illegal drug or
used a prescription medication for nonmedical reasons
at least once in the past three months [24] (equivalent to
a DAST-10 score greater than 0 [25,26]); currently
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continue such care for the next year; English speaking
and able to read and understand screening and assess-
ment forms (6th grade literacy); and having a phone, easy
access to a phone with voicemail, or access to e-mail in
order to facilitate scheduling.
To enhance external validity there are few baseline
exclusion criteria. They include having attended formal
treatment for substance abuse (excluding self-help
groups such as Alcoholics Anonymous) in the past
month; life-threatening medical illness (potential mortal-
ity in next year); severe cognitive impairment or active
psychosis interfering with cognitive ability to process the
BI (based on performance during consent and assess-
ment); or active high risk suicidality [27].
There are two reasons for not excluding patients with
the most severe drug problems from this trial. First, al-
though some studies of BI for alcohol have found that
patients with alcohol dependence responded less well to
a BI than patients with less severe abuse or hazardous
drinking, Field recently found that patients with alcohol
dependence responded better to a BI than those with
less severe problems [28] and Cobain found hospital-
based BI effects to be independent of baseline depend-
ence or medical comorbidity [29]. Second, even if a BI
were inadequate as a stand-alone treatment for safety
net patients with severe drug dependence, BI may prove
to be a valuable referral mechanism for getting these
patients to more intensive chemical dependency treat-
ment, as it did in WASBIRT [30]. For these reasons, we
include individuals across the full range of drug use and
abuse in the present study. To balance drug use severity
across BI and control groups, we use the DAST-10 score
as a stratifying variable.
Rationale for selecting primary care versus ED setting
Providing a BI in the ED setting has a number of advan-
tages. For example, the ED is where individuals with
substance-related injuries and acute medical problems
present for urgent care. This setting maximizes the
chance for a “teachable moment” and has more “high
risk” individuals with a greater potential for high cost
medical care use. Although the prevalence of illicit drug
use is greater in the ED [31], primary care sees a larger
number of individuals on an annual basis and has a ser-
vice system more amenable to ancillary behavioral treat-
ments because of its chronic illness focus. Furthermore,
risk reduction in this setting can potentially prevent
higher cost ED and hospital visits since patients in safety
net medical settings are less likely to utilize primary care
in a ‘health maintenance’ fashion and more likely to
schedule primary care appointments on an ad hoc basis
when they have emergent medical problems. In indivi-
duals with hazardous drug use, some of these problemsare substance-related, creating ‘teachable moments’ like
those seen in patients seeking care in the ED. Finally, a
host of prior studies have shown that integration of
mental health into primary care is clinically and cost ef-
fective [32]. Integration of interventions for substance
abuse into primary care could have similar advantages,
especially since substance-related medical problems
could be addressed at the same time [33-35].
Assessing public-health benefits of the intervention
As described earlier, providing SBIRT services to a siz-
able proportion of individuals with hazardous substance
abuse in the ambulatory primary care setting has the po-
tential to result in a sizable public health benefit [15].
That is, the public health benefit, or population attribut-
able benefit, is far greater if one affects many people in a
small way than fewer people in a larger way. As such, it
is important to examine this benefit, especially at a time
when providers, health care administrators, and policy
makers are being increasingly required to rein in health
care costs that are spiraling upward while resources for
public health care are diminishing [36]. Quantifying the
impact of brief interventions on the cost of health care,
public safety, and mortality represent critical informa-
tion needed to inform policy and program planning at
the local, state, and national levels. The current study
was designed to respond to this need by making preli-
minary estimates of the public health-related benefits of
the intervention including changes in use of inpatient,
emergency department, and outpatient medical services;
arrests; HIV infection; mortality; and costs through the
use of administrative data.
Keeping the assessment brief but accurate
To enhance external validity, we are limiting the inten-
sity and frequency of assessment to bridge the distance
between a traditionally rich and extensive efficacy study
assessment battery and what might more routinely be
performed as part of quality assurance when an SBIRT
program is implemented. This decision also enhances in-
ternal validity because prolonged assessor contact with
significant focus on substance-related measures (in the
usual care arm) may have an unintended therapeutic ef-
fect as noted by other experts [15,37-41]. That is, the
more elaborate assessment of the typical efficacy study
would likely last longer than the actual BI itself and
might confound the comparison condition of ECAU. As
such, we are limiting assessment to 30 minutes, a du-
ration which has been shown to not have an interven-
tion effect in recent analysis [42]. At the same time, we
are supplementing our assessment with administrative
data that will allow us to verify medical services received
and whether individuals had participated in substance
abuse treatment recently or had received a BI outside of
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determine whether individuals with urine screens positive
for opiates might be receiving prescription opiates for
related painful medical conditions as well as whether there
is documentation of excess use, withdrawal symptoms,
requests for early prescriptions, or visits to the ED to ob-
tain more opiates that can be used to recode self-reported
opiate use gathered during assessment.
Selecting study sites
The present study is sited in primary care clinics
affiliated with a large urban safety net medical center.
One advantage of this siting is that patients receive all of
their urgent and emergent medical care at the medical
center, making it possible to track medical utilization
over time. Practical considerations require that partici-
pating clinics serve a high volume of patients and, ad-
ditionally, have evidence that a reasonable proportion of
patients (say, 25% or more) are likely to have problem
drug use. Insuring sufficient numbers of women in the
sample to maximize generalizability is another important
consideration. Initially it was estimated that all study
participants could be recruited from the pool of patients
who sought treatment at one of four primary care
clinics. After the first year, however, we were unable to
recruit the numbers of patients suggested by our original
estimates, which required us to expand to three ad-
ditional medical clinics. Furthermore, the economic
downturn prompted some clinic infrastructure and ser-
vice delivery changes at the safety net medical center
which operates these clinics, creating additional un-
anticipated challenges, for example, waiting lists for new
patients and deciding to move all female primary care
patients without specific obstetric and gynecologic needs
to other primary care clinics.
Specific nature of the intervention
The study employed a total of 17 interventionists. We
decided to have social workers who were already
employed in each of the clinics conduct the BI as they
were more available and less costly than primary care
physicians. We began with eight social workers and, as
the study evolved, required additional interventionists.
We recruited three additional social workers who were
working in the clinics, two social workers not working
in the clinics, two clinical psychology doctoral students,
and two bachelor-level individuals with experience con-
ducting structured clinical interviews.
The intervention consists of a single-encounter BI
followed by an attempted single phone booster contact
one week later. The BI is delivered using an MI ap-
proach following a rich history of successful MI-based
SBIRT interventions in primary care and trauma center
trials for hazardous alcohol use over the last 15 years[18,43-45]. Also, a central consideration in choosing MI
for delivery of the intervention was its documented lar-
ger effect sizes with ethnic minorities [46]. With every
patient, interventionists perform standard elements or
“clinical tasks”. The clinical tasks of the counseling ses-
sion include orienting patients to the purpose of the ses-
sion, telling patients their screening results, discussing
options for change, and giving patients information
about links between drug abuse and medical conditions.
Interventionists perform these tasks using the highest
quality MI skills of which they are capable. Two exam-
ples may serve to clarify how one might perform the
clinical tasks using an MI style. One example is, when
giving screening feedback, the interventionist uses a
standard explanation of the DAST-10 score to help the
patient understand the meaning of their score while, at
the same time, using specific MI skills to handle any ar-
guing or objections from the patient that may arise upon
hearing their score. These skills might include reflecting
the patient’s surprise or gleaning from the patient’s argu-
ments apparent personal strengths such as having a
genuine concern about whether drugs are hurting him/
her. A second example of integrating MI illustrates our
effort to enhance the potential “teachable moment” of
the protocol. This task involves focusing the interview
on specific adverse health consequences of particular
drugs. To this end, MI skills such as “Ask-Tell-Ask”
might be deployed (e.g., Ask patient what he/she already
knows about the effects of crack smoking on the lungs.
Tell patient how crack might be exacerbating their
chronic cough, and Ask patient what they think about
that information). In this patient-centered spirit, the
intervention focuses on the drug of most concern to
patients who use multiple drugs.
All brief interventions are audio-recorded and are
scored by trained coders using the Motivational Inter-
viewing Treatment Integrity (MITI) instrument [47] to
monitor potential drift in the MI protocol as well as to
assess for Aim 2 levels of fidelity to MI. While all inter-
ventionists are required after training to reach and main-
tain a specified threshold of MI skill, it is expected there
will still be adequate variation in MI skills to allow for
an analysis of study Aim 2—testing the degree to which
fidelity to the BI model is associated with better
outcomes.
It is possible that the intervention may be too brief to
have a treatment effect for some patients with severe
drug disorders. However, the intervention could still
contribute to a referral effect in that patients who parti-
cipated in a BI may be more likely to seek treatment
after being referred. Whether to refer a patient to treat-
ment is determined using the DAST-10 score as a guide
in concert with the spirit of the patient-interventionist
interaction. After the intervention, a referral to
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hostile to the idea and when the DAST-10 score is 6 or
greater in accordance with existing norms [21]. A
DAST-10 score less than 3 does not generally trigger a
referral. For DAST-10 scores between 3 and 5, the inter-
ventionist uses their judgment as to whether to refer
based on information obtained from the BI. When in
doubt, or whenever the patient asks for help, the inter-
ventionists refer. In addition, to preserve internal valid-
ity, all individuals assigned to the BI group are given
the same referral sheet as individuals assigned to the
ECAU group.
A booster session has been shown to enhance the
effects of a BI [48] and, for this reason, is included in
the present study. The booster session consists of a ten-
minute follow-up call approximately one week after the
initial intervention. During the call, the interventionist
references the plan or option decided upon in the initial
intervention and uses MI to follow-up on ambivalence
about enacting the plan, generating change talk, or com-
mitting to specific goals.Training the interventionists
Interventionist training was designed to support the
provision of consistently high quality BIs across clinics,
between interventionists, and within interventionists over
time. It consists of an 8 to 16 hour BI workshop supple-
mented by one hour of individual supervision once a
week for the following three to five weeks. During the
individualized supervision, trainees receive tailored
coaching with the MI trainer (CD) and feedback on their
audio-taped role-plays with standardized patients using
their MITI scores. The training protocol was designed to
be an enhanced version of manualized trainings recog-
nized for their effectiveness that have been conducted
both nationally and internationally [18,44,45,49-53].Screening and assessment
It is important to be able to identify individuals with
problem drug use reliably and validly, and to be able to
do so without interfering with day-to-day medical clinic
operations. A brief screening procedure was devised to
assess individuals for eligibility in the study; it involves
the patient completing a form which includes eligibility
criteria and two screening questions: (i) to identify any
illicit drug use in the past three months, and (ii) to iden-
tify any non-prescribed medication use in the past three
months. The screening questions are based on a single-
item screening test found to reliably identify drug use in
a primary care population [24]. Screen-eligible indivi-
duals interested in enrolling in the study are then con-
sented and assessed in a private area on-site with a
modified battery (see below) and those randomized tothe BI group are provided a BI at the earliest possible
time, usually the same day.
Assessment battery and table
The DAST-10 was selected as an instrument to assess
substance abuse severity because of its widespread use
over the last decade (including the SAMHSA SBIRT trial
in Washington State), its known psychometric proper-
ties, the fact that it is self-administered and takes less
than 5 minutes to complete, and because it provides a
range of scores that have known convergent validity with
substance abuse severity defined by other clinical means
[21]. This latter characteristic is crucial in stratifying the
sample for drug abuse severity prior to randomization.
In order to be consistent with the majority of extant
BI studies on alcohol and drug abuse, we use a 12-
month assessment window and conduct assessments at
baseline, 3, 6, 9, and 12 months. Research assistants
conduct follow-up interviews and are blinded to a parti-
cipant’s intervention versus control group status.
Assessments are carried out in-person whenever pos-
sible, with phone interview as a backup option. Vigo-
rous outreach is used to complete assessments. The
assessments are brief to minimize any unintended inter-
vention effects and to allow the BI to be conducted as
close as possible to the screening procedure although
we recognize that in-person assessments could poten-
tially contribute to an unintended effect favoring the
comparison group. Assessment measures and the times
they are administered are summarized in Table 1.
We supplement self-report data collected from partici-
pants with data from several administrative sources.
These are summarized in Table 2. For the administrative
sources, the follow-up time ranges from a minimum of
12 months to a maximum of 24 months, depending on
data availability during the time of the study. Obtaining
data for a minimum of 12 months will facilitate esti-
mates of public health effects, given prior results of
functional effects for substance abuse interventions
[13,53,54].
Choosing the primary outcome variables
Outcome variables were selected specific to each of the
study’s aims:
Aim 1
For the first aim—to examine whether BI is effective at
improving drug use, psychiatric outcomes, select psycho-
social outcomes, and attendance in drug abuse treat-
ment—it is important to reliably capture changes in
drug use as well as in other variables in as brief a period
of time as possible. Because of its widespread use, bre-
vity, and reliability, the validated short form of the Ad-
diction Severity Index (ASI), the ASI-Lite [55], was
Table 1 Assessment measures
Measure Baseline 3 months 6 months 9 months 12 months
Preliminary Informed consent + 1-item screen X
Full informed consent X
HIPAA Authorization X
Consent for Follow-up Procedures X
Release of Information X
DAST-10 X
Thoughts about Drug Use X X X X X
Addiction Severity Index (ASI) -Lite X X X X X
Treatment Services Review (TSR) X X X X X
HIV Risk-Taking Behavior Scale X X X X X
EQ-5D-3L X X X X X
Urine Sample X X X X X
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vices Review (TSR) [56]. To further minimize time bur-
den on participants, we only administer items required
to compute the ASI composite scores (half the total
items) [55].
In order to identify changes in illicit drug use, we use
items from the ASI drug section to measure days of any
drug use. A urine toxicology screen is used to supple-
ment participants’ responses. In addition, we use the
ASI composite scores as comprehensive measures of
participants’ medical, psychiatric, legal, family/social,
and employment status. The HIV Risk-Taking Behavior
Scale is used to assess risk-taking behavior among intra-
venous drug users [57] and the EQ-5D-3L is used to
measure health status [58]. Administrative data are used
to supplement ASI data on legal (e.g., arrests) effects.
Changes in attendance in drug treatment are obtained
from the TSR as well as from state administrative chem-
ical dependency treatment records.
Aim 2
The second aim—to test whether fidelity to the BI model
is associated with better outcomes—requires a reliable
way to assess fidelity. Because of is reliability, cost effect-
iveness, and brevity, the MITI, which provides a standar-
dized way to rate session audiotapes for degree of MI
content, was selected for this purpose [47]. Outcomes
for this aim include changes in illicit drug use and drug
treatment attendance as measured in the first aim.
Aim 3
For the third aim—to estimate the impact of BI on select
public health outcomes that are directly related to the
hazardous effects of illicit drug use—it is important to
identify objective measures reflective of the conse-
quences of illicit drug use. Because of their established
tie to illicit drug use, we selected changes in utilizationof health care services (including ED visits, inpatient
hospitalizations, and hospital days), arrests, and death,
as captured in state administrative records [59,60].
Aim 4
The fourth aim—to estimate the cost of the intervention,
potential cost offsets, and its incremental cost effective-
ness —requires valid cost data. The cost of the interven-
tion includes the cost of personnel, materials, and
locations for start-up and implementation activities
required to screen for drug use and provide a BI. Poten-
tial cost offsets will be examined for emergency room
visits, outpatient visits, and hospital admissions. The
cost measure for all of these medical services includes
the direct and indirect costs of providing medical care
from the provider perspective. If indicated by study
results, we will also assess cost offsets generated by
reductions in arrests. If the BI is found to reduce drug
use, we will further estimate the incremental cost of the
BI intervention compared to its incremental effect on
drug use.
Data analysis
Analyses will compare outcomes for the BI and ECAU
groups following the intent-to-treat principle. If indi-
cated, these models will take into account baseline dif-
ferences between the two groups. Time trend models
will be used to examine temporal effects, specifying time
of assessment as a categorical variable (baseline, 3, 6, 9,
and 12 months). Because assessments are nested within
patients and patients are nested within clinics and inter-
ventionists, analyses will be conducted with linear mixed
models. Clinics will be treated as fixed effects, as they
were purposively sampled. In contrast, interventionists
were assigned to patients based on availability when a BI
had to be administered. For interventionists, random
effects will therefore be specified and tested.
Table 2 Administrative data sources





Washington State Department of Social and
Health Services (DSHS), Division of Behavioral
Health and Recovery (DBHR)
Record of participation in publicly-funded
chemical dependency treatment or
detoxification services
- Number of days
with outpatient
treatment visit













- HIV diagnosis date
- Hepatitis diagnosis
date
















Washington State Patrol All arrests in Washington State including arrest
date, nature of offense, level of offense
- Number and type
of felony arrests






Washington State DOH Vital Records Information about decedent (e.g., age, date of
birth, race), place of death, cause-of-death
codes, injury information
- Date of death
- Cause of death
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Power analyses were conducted with PASS software version
08.0.5 [61]. For the primary outcome of drug use reduction,
we computed power for the last point in time when data
are collected from participants. We expect to enroll 1,000
study participants, 500 each per BI and ECAU group. As-
suming an overall response rate of 75%, we would have data
from 375 individuals per group at 12 months. According to
results from the WASBIRT study, the frequency distribu-
tion of number of days drugs were used in the past 30 days
follows a Poisson distribution. For individuals who received
a BI in WASBIRT, at baseline, average days of drug use in
the past 30 days were 3.8 for moderate risk users, 7.0 for
high risk users who received only a BI, and 8.7 for high risk
users who received a BI and brief therapy and/or chemical
dependency treatment. Based on these averages, the study
would have 89% power to detect as low as a 2.5% reductionin average drug use days for moderate risk users, at a two-
sided alpha level of .05, and an R2 between BI indicator
variable and other covariates of .25. If the R2 between the
BI indicator variable and other covariates were 0.5 (a con-
servative assumption), the power to detect as low as a 2.5%
reduction in average drug use days for moderate risk users
is 74%; the power to detect a 5% reduction in average drug
use days is 99%. For high risk users, the power to detect a
reduction in drug use of at least 2.5% is higher. The end-
status analysis assumed for these power calculations is con-
siderably conservative, as data from earlier points in time
are not used. Thus, the proposed study has sufficient power
to address the first two specific aims.
Discussion
The present study was designed to evaluate the impact
of a BI on patients with problem drug use in a primary
Krupski et al. Addiction Science & Clinical Practice 2012, 7:27 Page 9 of 10
http://www.ascpjournal.org/content/7/1/27care setting within a safety net system of care and, in so
doing, to be among the few randomized controlled trials
of BI for drug abuse in the general medical setting for
non-treatment seekers. In addition to capturing post-
intervention changes in drug use, psychiatric outcomes,
and other psychosocial variables, it also quantifies the
impact of BI on the cost of health care, public safety,
and mortality in order to inform policy and program
planning relative to problem drug use at the local, state,
and national levels. As such, it will serve as a policy-
relevant trial with broad external validity
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